Drugs / Keguan-1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04251871 | Jan 2020 → Jan 2021 | COVID-19 | Beijing 302 Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Keguan-1 | “A putative ARDS-suppressing drug Keguan-1 was first developed and then evaluated by a randomized, controlled two-arm trial.” PMID 32676976 ↗ Jul 2020 |
| Modality | Traditional medicine (herbal / TCM) | “To develop a new Chinese medicine (CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome (ARDS) in COVID-19 patients.” PMID 32676976 ↗ Jul 2020 |
| Route | Oral | “Traditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days.” NCT04251871 ↗ |